Hamed Kamal's Form 4 filing
Spero Therapeutics, Inc. (SPRO) · filed Feb 5, 2024
- Accession no.
- 0000950170-24-011491
- Filed
- Feb 5, 2024
- Trade date
- Feb 1-2, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $38.5K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hamed KamalCIK 0001946366 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 1, 2024 | Common Stock | AGrant or awardAcquired | +239,731 | $0.00 | $0 | 816,192 | Direct | |
| Feb 2, 2024 | Common Stock | SSaleDisposed | −28,075 | $1.37 | −$38,462.75 | 788,117 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.